Incyte Corporation Other Non-Current Liabilities 2010-2024 | INCY

Incyte Corporation other non-current liabilities for the quarter ending September 30, 2024 were $0.311B, a 2.67% increase year-over-year.

  • Incyte Corporation other non-current liabilities for 2023 were $0.323B, a 13.76% increase from 2022.
  • Incyte Corporation other non-current liabilities for 2022 were $0.284B, a 2.27% increase from 2021.
  • Incyte Corporation other non-current liabilities for 2021 were $0.277B, a 2.96% decline from 2020.

Incyte Corporation Other Non-Current Liabilities 2010-2024 | INCY

  • Incyte Corporation other non-current liabilities for 2023 were $0.323B, a 13.76% increase from 2022.
  • Incyte Corporation other non-current liabilities for 2022 were $0.284B, a 2.27% increase from 2021.
  • Incyte Corporation other non-current liabilities for 2021 were $0.277B, a 2.96% decline from 2020.
Related Stocks
Company NameMarket
Cap
Vertex Pharmaceuticals Incorporated (VRTX)$133.1B
Gilead Sciences, Inc. (GILD)$120.2B
Regeneron Pharmaceuticals, Inc. (REGN)$91B
CSL Limited Sponsored ADR (CSLLY)$90.5B
GSK PLC Sponsored ADR (GSK)$75.2B
Biogen Inc. (BIIB)$25.2B
Illumina, Inc. (ILMN)$24B
Moderna, Inc. (MRNA)$18B
Genmab A/S Sponsored ADR (GMAB)$15.3B
Vaxcyte, Inc. (PCVX)$13.3B
Insmed, Inc. (INSM)$13.2B
Bio-Techne Corp (TECH)$12.1B
Exelixis, Inc. (EXEL)$10.4B
Revolution Medicines, Inc. (RVMD)$10.2B
QIAGEN N.V. (QGEN)$10B
Intra-Cellular Therapies Inc. (ITCI)$9.7B
Exact Sciences Corporation (EXAS)$9.5B
Roivant Sciences Ltd. (ROIV)$8.8B
Repligen Corporation (RGEN)$7.9B
Halozyme Therapeutics, Inc. (HALO)$7.8B
Viking Therapeutics, Inc. (VKTX)$7.6B
Legend Biotech Corporation Sponsored ADR (LEGN)$7.3B
Cytokinetics, Incorporated (CYTK)$6.8B
Nuvalent, Inc. (NUVL)$6.2B
Krystal Biotech, Inc. (KRYS)$5.7B
Avidity Biosciences, Inc. (RNA)$5.1B
Ultragenyx Pharmaceutical Inc. (RARE)$4.7B
Denali Therapeutics Inc. (DNLI)$4.5B
Immunovant, Inc. (IMVT)$4.5B
CRISPR Therapeutics AG (CRSP)$4.4B